# RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial

> **NCT06658977** · PHASE3 · TERMINATED · sponsor: **Macquarie University, Australia** · enrollment: 12 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis
- ALS

## Interventions

- **DRUG:** Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq)

## Key facts

- **NCT ID:** NCT06658977
- **Lead sponsor:** Macquarie University, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-11-15
- **Primary completion:** 2025-06-03
- **Final completion:** 2025-06-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** This is a rollover study following the Lighthouse II trial; it was scheduled to stop when the LH II trial was stopped/completed. The LH II trial has been prematurely terminated so, likewise, this study has also now been stopped.
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06658977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06658977, "RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06658977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*